Evidence map›Paper›PMID 42521762›Full record

ArticleMolecular psychiatry2026

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

Gregory H Jones, Jessica R Gilbert, Jenessa N Johnston, Nirmala Akula, Anton Schulmann, Miranda Arakelian, Shiyong Peng, Peixiong Yuan, Ewurakua A Winful, Mani Yavi and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Gregory H JonesExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA. GHJones@mdanderson.org.
Jessica R GilbertExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4194-6172
Jenessa N JohnstonExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2986-3179
Nirmala AkulaHuman Genetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Anton SchulmannHuman Genetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6323-4969
Miranda ArakelianExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0193-318X
Shiyong PengExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Peixiong YuanExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Ewurakua A WinfulExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Mani YaviExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Brandi QuintanillaDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA.
Abdel ElkahlounLaboratory of Cancer Genetics, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Ruin MoaddelBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Ioline D HenterExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Dede GreensteinExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.
Rodrigo Machado-VieiraDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4830-1190
Christopher M BartleyExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1391-4130
Bashkim KadriuExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3809-9451
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katy RezvaniDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark D KvartaExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1093-1648
Francis J McMahonHuman Genetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-9469-305X
Carlos A ZarateExperimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) NCTMH002857; NCTMH002844U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) ZIAMH002857; ZIAMH002844U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) Z01-AG00029
6 · The paper itself

Abstract

Despite distinct receptor targets, both ketamine and serotonergic psychedelics produce a rapid clinical response and share biological signatures that suggest convergence on common downstream molecular mediators. To identify shared biomarkers of rapid antidepressant response, this study integrated CSF proteomics from healthy volunteers (HVs) who received intravenous ketamine with transcriptomic analyses from induced pluripotent stem cells (iPSCs) derived from participants with treatment-resistant depression (TRD) and HVs; iPSCs were treated with ketamine, its metabolite (2 R,6 R)-hydroxynorketamine, lysergic acid diethylamide (LSD), or psilocybin. Multimodal clinical characterization (transcriptomics (n = 16 TRD; 11 HV), magnetoencephalography (MEG) (n = 30 TRD; 25 HV), and plasma cytokines (n = 39 TRD; 25 HV) were also performed on TRD and HV participants who received a single dose of intravenous ketamine (0.5 mg/kg) or placebo. Conserved immune pathways were identified across CSF and iPSC neurons with interleukin-15 (IL)-15 and monocyte chemoattractant protein-1 (MCP-1) emerging as key regulatory hubs. Transcriptomically, in whole blood, ketamine responders exhibited decreased IL-15 and elevated B-cell signaling pathways at baseline that were reversed post-treatment. At the protein level, plasma IL-7 levels (primary B-cell driver) correlated with baseline MEG gamma power, reaching brain-wide significance across all participants (main effect p

Identifiers

PMID42521762

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.